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Editors: Anton N. Sidawy and Bruce A. PerlerConformable stent graft for the treatment of acute,
complicated type B dissection: Multicenter clinical trial
Richard P. Cambria, MD, Mark F. Conrad, MD, Alan H.
Matsumoto, MD, Mark Fillinger, MD, Alberto Pochettino,
MD, Stephanie Carvalho, BA, Virendra Patel, MD, and Jon
Matsumura, MD
Objective: The treatment of acute, complicated type B
aortic dissection has evolved in the past several decades.
Thoracic endovascular aortic repair when anatomy is suit-
able, has been regarded as the preferable treatment to seal
the primary entry tear, redirect and re-establish adequate
true lumen ﬂow, and thereby promote aortic remodeling.
This study was designed to determine the safety and efﬁ-
cacy of a conformable thoracic endoprosthesis device for
patients with acute, complicated type B aortic dissection,
deﬁned as malperfusion or rupture or both.
Methods: Between January 2010 and January 2012, 50
patients with complicated type B aortic dissection from 26
sites in the United States were included in this prospective,
multicenter, nonrandomized single-arm study. The primary
safety end point was all-cause mortality through 30 days
after treatment, and the primary efﬁcacy end point was
exclusion of the primary entry tear (Core Laboratory adju-
dicated) at 1-month follow-up. Secondary end points
included false lumen thrombosis, dissection-based reinter-
vention rate, and aortic rupture.
Results: All device implants were successfully completed.
Six patients (12%) required additional device implantations
1 year from the index procedure. There was no conversion
to open repair at 1 year. Exclusion of the primary entry tear
at 30 days occurred in 97.5% of patients. All-cause mortality
through 30 days was 8%. Survival was 88% at 1 year and
85% at 2 years. At 1 year after treatment, 35.1% of patients
had experienced a decrease of 5 mm in overall diameter
in the treated segment of the aorta. From pretreatment to
the 36-month follow-up, the average minimum true lumen
area increased by 206.3 mm2, and the average maximum
false lumen area decreased by 313.4 mm2. The 30-day
stroke rate was 18%; none were fatal, and one permanent
deﬁcit occurred. Four patients (8%) experienced spinal cord
ischemia of any severity but without any permanent or
signiﬁcant deﬁcits. New aortic dissection (3 retrograde, 2 de
novo) occurred in ﬁve patients (10%). The secondary
intervention rate was 18%.*Full articles available online at www.jvascsurg.org
1078-5884/
http://dx.doi.org/10.1016/S1078-5884(15)00512-2Conclusions: Treatment with the conformable thoracic
endovascular aortic repair device produced favorable peri-
operative and intermediate level clinical and anatomic
outcomes. In particular, an operative mortality of 8% in this
cohort is comparable to that noted in a Society for Vascular
Surgery objective performance criteria publication. Late
survival in our cohort compares favorably with historical
data referable to complicated type B dissection.Multicenter Nellix EndoVascular Aneurysm Sealing system
experience in aneurysm sac sealing
Dittmar Böckler, MD, PhD, Andrew Holden, MBChB, Matt
Thompson, MD, Paul Hayes, MD, Dainis Krievins, MD, Jean-
Paul P. M. de Vries, MD, PhD, and Michel M. P. J. Reijnen,
MD, PhD
Objective: Despite improvements in endograft devices, oper-
ator technique, and patient selection, endovascular repair has
not achieved the long-term durability of open surgical aneur-
ysm repair. Persistent or recurrent aneurysm sac ﬂow from
failed proximal sealing, component failure, or branch vessel
ﬂow underpins a signiﬁcant rate of reintervention after
endovascular repair. The Nellix device (Endologix, Irvine, Calif)
employs a unique design with deployment of polymer-ﬁlled
EndoBags surrounding the endograft ﬂow lumens, sealing the
aneurysm sac space and potentially reducing complications
from persistent sac ﬂow.This retrospective analysis represents
the initial experience in consecutive patients treated with the
device in real-world practice.
Methods: This study was performed at six clinical centers
in Europe and one in New Zealand during the initial period
after commercialization of the Nellix device. Patients
underwent evaluation with computed tomography and
other imaging modalities following local standards of care.
Patients were selected for treatment with Nellix and
treated by each institution according to its endovascular
repair protocol. Clinical and imaging end points included
technical success (successful device deployment and
absence of any endoleak at completion angiography),
freedom from all-cause and aneurysm-related mortality,
endoleak by type, limb occlusion, aneurysm rupture, and
reintervention.
Results: During a 17-month period, 171 patients with
abdominal aortic aneurysms were treated with the Nellix
device and observed for a median of 5 months (range, 0-14
months).The 153male and 18 female patients withmean age
of 74  7 years had aneurysms 61  9 mm in diameter with
an average infrarenal neck length of 28  15 mm and
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was achieved in all but two patients (99%); one patient had a
type Ib endoleak and another had a type II endoleak.Through
the last available follow-up, type Ia endoleak was observed in
ﬁve patients (3%), type Ib endoleak in four patients (2%), and
type II endoleak in four patients (2%). There were eight limb
occlusions (5%), among which seven were evident at the 1-
month follow-up visit. Aneurysm-related reinterventions
were performed in 15 patients (9%).Therewere no aneurysm
ruptures or open surgical conversions.
Conclusions: This ﬁrst multicenter postmarket report of the
Nellix device for infrarenal abdominal aortic aneurysm
repair demonstrates satisfactory results during the initial
learning phase of this new technology. The rate of aneurysm
exclusion was high, and frequency of complications was low.
More deﬁnitive conclusions on the value of this novel
device await the results of the ongoing Nellix EVAS FOR-
WARD Global Registry and the EVAS FORWARD investiga-
tional device exemption trial.Performance of the Endurant stent graft in challenging
anatomy
Pieter P. H. L. Broos, MD, Rutger A. Stokmans, MD, Steven
M. M. van Sterkenburg, MD, Giovanni Torsello, MD, PhD,
Frank Vermassen, MD, PhD, Philippe W. M. Cuypers, MD,
PhD, Marc R. H. M. van Sambeek, MD, PhD, and Joep A. W.
Teijink, MD, PhD
Objective: This study aimed to compare perioperative and
postoperative outcomes after endovascular repair of
abdominal aortic aneurysms (AAAs) in patients with various
neck morphologic features.
Methods: Data from the Endurant Stent Graft Natural
Selection Global Postmarket Registry (ENGAGE) were used
for the analyses. Patients were categorized into three dif-
ferent groups according to proximal aortic neck anatomy:
regular (REG), intermediate (INT), and challenging (CHA).
REG was deﬁned as AAAs with a proximal neck 15 mm
combined with a suprarenal angulation (a) 45 degrees
and an infrarenal neck angulation (b) 60 degrees. INT was
deﬁned as AAAs with a proximal neck of 10 to 15 mm
combined with a 45 degrees and b 60 degrees or with a
proximal neck of >15 mm combined with a 60 degrees
and b = 60 to 75 degrees or a = 45 to 60 degrees and b 75
degrees. CHA was deﬁned as infrarenal necks that exceed at
least one of the three deﬁning factors.
Results: Overall, 925 patients (75.9%) had REG anatomy,
189 patients (15.5%) had INT anatomy, and 104 patients
(8.5%) had CHA anatomy. Patient demographics and risk
factors were similar. There was a signiﬁcant difference in
AAA diameter between the REG and CHA groups (59.4 mm
vs 65.2 mm; P < .001). Technical success was similar among
groups (REG 99.1% vs INT 99.5% vs CHA 97.1%). There were
no differences in mortality or the need for secondary pro-
cedures within 30 days or at 1 year. A signiﬁcantly higher
rate of type I endoleaks within 30 days was seen in CHA
compared with REG (adjusted odds ratio, 0.15; 95%conﬁdence interval, 0.05-0.46) and INT (adjusted odds ratio,
0.08; 95% conﬁdence interval, 0.01-0.70), but there was no
difference at 1-year follow-up.
Conclusions: This real-world, global experience shows
promising results and indicates that endovascular AAA
repair with the Endurant stent graft (Medtronic Vascular,
Santa Rosa, Calif) is safe and effective in patients with
challenging aortic neck anatomy. However, long-term fol-
low-up of patients is required to conﬁrm results.Comparison of domain-speciﬁc cognitive function after
carotid endarterectomy and stenting
Panos Kougias, MD, MS, Robert Collins, PhD, Nicholas Pas-
torek, PhD, Sherene Sharath, MPH, Neal R. Barshes, MD,
MPH, Katie McCulloch, MA, George Pisimisis, MD, and
David H. Berger, MD, MHCM
Background: Observational data indicate that carotid artery
stenting (CAS) is associated with higher incidence of sub-
clinical cerebral microemboli than carotid endarterectomy
(CEA). We hypothesized that CEA would be associated with
superior performance on detailed domain-speciﬁc cognitive
testing compared with CAS.
Methods: Patients with >80% asymptomatic carotid artery
stenosis were randomized to CEA or CAS with side of
stenosis balanced across condition. A robust battery of tests
was used to assess the cognitive domains of attention,
memory, mood, visual-spatial skills, motor ability, process-
ing speed, and executive functioning 10 days pre-
operatively and postoperatively at 6 weeks and 6 months.
Tests were administered using standardized conditions and
were scored by individuals blinded to treatment allocation.
Results: Baseline cognitive performance was similar between
CAS (n ¼ 29) and CEA (n ¼ 31) groups (P > .05). Relative to
baseline, verbal and visual memory and attention functions
substantially improved in the CAS and CEA groups at 6
months (multiple cognitive tests achieved statistical sig-
niﬁcance). Compared with CEA, cognitive processing speed
(Stroop Color test: 9.0 vs 7.3, P = .04; and Stroop Word test:
9.0 vs 7.4, P = .05) was superior in the CAS group at 6 weeks.
Executive functioning (phonemic verbal ﬂuency: 10.6 vs 8.4,
P = .043) and motor function (Grooved Pegboard of non-
dominant extremity: 45.7 vs 38.9, P = .022) were also superior
in the CAS group at 6 months. Tests of attention, memory,
and visual-spatial skills were similar between CAS and CEA
patients at 6 weeks and 6 months.
Conclusions: Carotid revascularization improves memory and
attention within the ﬁrst 6 postoperative months. Compared
with CEA, CAS produces improvements in cognitive processing
speed, executive functioning, and motor function.Outcomes of completion imaging for lower extremity
bypass in the Vascular Quality Initiative
Karen Woo, MD, Owen P. Palmer, MD, Fred A. Weaver, MD,
and Vincent L. Rowe, MD
268 AbstractsObjective: The objective of this study was to determine the
association of intraoperative completion imaging (CI) for
lower extremity vein bypass to a below-knee target with
primary patency in the Vascular Quality Initiative.
Methods: The Vascular Quality Initiative database was
queried from January 2003 to October 2013 for lower
extremity bypass (LEB) procedures that were elective, had an
indication of occlusive disease, used a single-segment greater
saphenous vein conduit, and had a below-knee target. LEBs
with inﬂow arteries above the knee and below the knee were
included. LEBs with concomitant endovascular procedures
were excluded. CI was deﬁned as completion angiography,
completion duplex ultrasound, or both. The end points were
primary patency at discharge and at 1 year. Multivariable
analysis was performed controlling for patient demographics,
comorbidities, bypass characteristics, and center.
Results:Of 14,284 LEBs that were performed during the study
period, 3147 satisﬁed the inclusion and exclusion criteria. Of
1457 (46%) that underwent CI, 287 (20%) underwent duplex
ultrasound, 1116 (77%) underwent angiography, and 54 (3.7%)
underwent both duplex ultrasound and angiography. There
were more patients in the CI group with a history of smoking
and a bypass graft crossing the knee. There was no difference
in primary patency at discharge between the two groups (CI,
93.2% vs no CI, 93.8%; P = .52). Of the patients who underwent
CI, the discharge primary patency was 95.1% for completion
duplex ultrasound vs 92.8% for completion angiography (P =
.17). On multivariable analysis, there was no signiﬁcant asso-
ciation of CI with discharge primary patency (P = .69). The 1-
year primary patency was 63% in the CI group vs 68% in the no
CI group (P = .051).The 1-year primary patencywas 60% for the
duplex ultrasound group vs 65% for the angiography group (P =
.61). On multivariable analysis, there was no signiﬁcant asso-
ciation of CI with 1-year primary patency (P = .69).
Conclusions: In electively performed LEBs using single-seg-
ment saphenous vein to a below-knee target artery for
occlusive disease, CI does not inﬂuence primary graft
patency at discharge or at 1 year.A novel tool for three-dimensional roadmapping reduces
radiation exposure and contrast agent dose in complex
endovascular interventions
Lars Stangenberg, MD, PhD, Fahad Shuja, MD, Bart Care-
lsen, PhD, Thijs Elenbaas, PhD, Mark C. Wyers, MD, and
Marc L. Schermerhorn, MDObjective: The volume and complexity of endovascular
procedures are increasing. Multidetector computed
tomography (CT) made precise three-dimensional (3D)
planning of these procedures possible, but intraoperative
imaging, even with the use of modern ﬂat-panel detectors,
is limited to two dimensions. Flat detectors, however, allow
C-arm cone-beam CT. This technology can be used to
generate a 3D data set that can be fused with a pre-
operative high-resolution CT scan, thus generating a live 3D
roadmap. We hypothesized that use of a novel image
fusion software, VesselNavigator (Philips Healthcare, Best,
The Netherlands), facilitates precise and expeditious pro-
cedures and therefore reduces radiation exposure and
contrast agent dose.
Methods: A retrospective review of patients undergoing
standard aortobi-iliac endovascular aneurysm repair at our
institution between January 2011 and April 2014 was per-
formed. Conventional imaging was compared with Vessel-
Navigator-assisted imaging, and a matched analysis based
on body mass index (BMI) was performed because of the
dependence of radiation dose on body habitus. Outcome
parameters were procedure time, ﬂuoroscopy time, radia-
tion, and contrast agent dose.
Results: A total of 75 patients were identiﬁed. After
matching based on BMI, control and VesselNavigator groups
each had 16 patients with BMI of 27.0  3.6 kg/m2 and
27.0  3.6 kg/m2, respectively (mean  standard devia-
tion). R2 was 6.37 Ã 10â
ˇ
7. Radiation dose measured as air
kerma was lower with VesselNavigator (1067  470.4 mGy
vs 1768  696.2 mGy; P = .004). Fluoroscopy time was
shorter (18.4  6.8 minutes vs 26.8  10.0 minutes; P = .01)
and contrast agent dose was lower (37.4  21.3 mL vs 77.3
 23.0 mL; P < .001) with VesselNavigator compared with
control. Procedure time was also shorter with VesselNavi-
gator (80.4  21.2 minutes vs 110.0  29.1 minutes; P =
.005).
Conclusions: Image fusion using VesselNavigator enhances
the functionality of conventional ﬂuoroscopy in standard
endovascular aneurysm repair. It reduces radiation expo-
sure to patients and providers. It also limits the amount of
contrast agent and shortens the overall procedure length.
The beneﬁt of this technology is demonstrated on this
typically straightforward procedure but may be even more
useful for complex procedures.
